ASCO GI 2023 | Unmet needs in advanced esophageal cancer

Ken Kato, MD, PhD, National Cancer Center Hospital, Tokyo, Japan, provides an overview of remaining challenges in the management of advanced esophageal cancer. Despite the approval of immune checkpoint inhibitors such as pembrolizumab, a number of patients will progress of these therapies. Novel agents such as amivantamab, antibody-drug conjugates (ADCs), and combination therapies such as nivolumab and ipilimumab are needed to enhance patient outcomes. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.